Stentys Closes $22+ Million Series `B` Total Financing Led By Sofinnova Partners and Scottish Equity Partners (SEP) with $4.2 Million from New Investor Crédit Agricole Private Equity

"I am more than ever convinced that the Company is uniquely positioned to
develop its breakthrough approach for treating acute myocardial infarction and
bifurcation lesions." - Jacques Séguin, M.D., Ph.D., co-founder of Stentys and
founder of CoreValve
PRINCETON, N.J. and PARIS--(Business Wire)--
Medical device pioneer Stentys announced today that it has secured the second
tranche of its Series B financing from Sofinnova Partners and SEP-closing an
additional $4.2 million investment from new investor Crédit Agricole Private
Equity-bringing the total B round financing to more than $22m.

Stentys was founded in 2006 to develop a new-generation stent designed for
treatment of acute myocardial infarctionandcoronary artery bifurcations.

Treatment of acute myocardial infarction accounts for 50% of stent implantations
worldwide, a $5 billion market. However, existing balloon expandable stents do
not ensure optimal contact with the artery wall, and clotting can occur between
the stent and the coronary wall and within the stent itself. Stentys`
self-expanding stent is constantly applied to the vessel surface and ensures
immediate and permanent optimal apposition during thrombus and vessel spasm
relief, therefore avoiding any malapposition and subsequent clotting.

"Stentys has completed an initial 40 patient clinical trial demonstrating safety
and efficacy of the stent. This second financing tranche of the Series `B` round
will enable Stentys to obtain CE marking and begin European marketing of the
first self-expanding stent platform for the treatment of myocardial infarction,"
said Gonzague Issenmann, Stentys` CEO.

Antoine Papiernik, Managing Partner with Sofinnova Partners, Stentys` initial
and largest institutional investor, commented, "The ability of the company to
add an investor to the syndicate in this very difficult financing environment
bears strong testimony to the strength of the Stentys` platform."

Brian Kerr, Partner at SEP, stated, "We are delighted to have the added
investment from Crédit Agricole Private Equity. This additional funding
underscores the significant potential that Stentys` platform presents in the
treatment of heart attacks and bifurcation lesions."

Alexia Perouse, Director at Crédit Agricole Private Equity`s Venture Capital
team, added, "I am delighted to be joining the Stentys board and to have the
opportunity to contribute to the growth of the company and its game-changing
technology to treat heart attacks."

Jacques Séguin, M.D., Ph.D., co-founder and Chairman of Stentys, added, "I am
delighted to see Stentys reinforce its financial base. I am more than ever
convinced that the Company is uniquely positioned to develop its breakthrough
approach for treating acute myocardial infarction and bifurcation lesions."

About Crédit Agricole Private Equity

Crédit Agricole Private Equity is an AMF-accredited asset management subsidiary
of Crédit Agricole S.A., specialising in direct investment in non-listed
companies. A multi-specialist player in the private equity market, it has a team
of 50 investors operating in a variety of fields (LBO & Expansion, Venture
Capital, Mezzanine, Co-Investment, Renewable Energy, PPP Infrastructure, etc.),
and manages €2.8 billion through various private equity vehicles (FCPRs, SICARs,
FCPIs and SCRs). The 12-strong venture capital team manages €375 million through
FCPIs, and Crédit Agricole Private Equity`s portfolio currently includes a
number of cutting-edge medtech companies such as SuperSonic Imagine, Circulite,
Biospace, EyeTechCare and SpineGuard.
www.ca-privateequity.com

About Scottish Equity Partners

SEP is a leading European venture capital firm with offices in Glasgow and
London. It helps entrepreneurs to create world class companies. The investment
team, which is one of the most experienced in Europe, has backed and built
global leaders in the information technology, healthcare and energy-related
technology sectors. SEP`s portfolio of leading-edge companies includes: ArkEx,
CamSemi, Daysoft, Gigle, ipaccess, picochip, Skyscanner, Tideway, VirtenSys.
Zeus.
www.sep.co.uk

About Sofinnova Partners

Sofinnova Partners is an independent venture capital firm based in Paris, France
that specializes in investments in early stage companies and corporate spin-offs
in life sciences and technology. Since 1972, the firm has financed over 450
companies, many of which have gone public or have been acquired, and currently
manages over €1 billion in assets. Sofinnova`s experienced team and hands-on
approach in nurturing and supporting portfolio companies from initial financing
to successful exit have created market leaders and multiplied revenues.
www.sofinnova.fr.

About Stentys

Based in Princeton, N.J., and Paris, Stentys intends to make treatment of
complex blocked coronary arteries as simple and effective as a conventional
stenting procedure. Stentys was co-founded by Gonzague Issenmann and Jacques
Séguin, M.D., Ph.D., founder of CoreValve, which was acquired this year by
Medtronic for $700 million plus milestones.

Crédit Agricole Private Equity
Martine Sessin-Caracci, + 33 1 43 23 90 88
martine.sessincaracci@ca-privateequity.fr
or
Sofinnova Partners
Antoine Papiernik, + 33 1 53 05 41 00
apapiernik@sofinnova.fr
or
SEP
Valerie Darroch, + 44 7970 737708
valerie.darroch@sep.co.uk
or
Stentys
Ronald Trahan Associates Inc.
Ronald Trahan, + 1-508-359-4005, x108
APR, President
rctrahan@ronaldtrahan.com

Copyright Business Wire 2009